Ed Yelin, PhD


In the broadest terms, Dr. Yelin’s research has emphasized the health policy issues related to chronic disease. Much of the research has been conducted about persons with various forms of musculoskeletal disease with funding from NIAMS, although he has also conducted studies about the impacts of asthma and other pulmonary conditions, cancer, HIV-related conditions, mental illness, and disabilities associated with chronic disease. Dr. Yelin is perhaps best known for his work on employment among persons with arthritis and other chronic diseases. Prior to his research in this area, work disability was believed to be almost exclusively determined by the severity of disease or by the extent of benefits one could expect to receive if one left the labor force. His research has shown that, on the micro level, the way work is structured is a much more important factor and that, on the macro level, the structure of the labor market has a profound impact on work disability rates. This work has resulted in over 50 publications on employment

A second major thread to his research concerns studies of the impact of changes in the health care system on persons with arthritis. Up to this point, most of the work in this area has been done with a large panel of persons with rheumatoid arthritis originally derived from the practices of a random sample of Northern California rheumatologists; some of the members of the panel have been followed for as long as 20 years through annual structured telephone interviews and periodic updates from their physicians. Briefly, using this data he has shown that the pre-paid group practice form of health maintenance organization provides similar kinds and amounts of care for rheumatoid arthritis and has achieved similar outcomes as fee-for-service settings over as long as eleven years. One exception indicates that the use of biological agents for the treatment of rheumatoid arthritis occurs less frequently in managed care settings than in fee-for-service, principally initiation of biological agents occurs less frequently in the former settings. As part of the research on the impact of the health care system, he has shown that rheumatologists achieved significantly better outcomes than generalist physicians, and their patients use fewer resources. A R01 grant jointly funded by the Agency for Health Care Research and Quality and NIAMS, two funded by the Arthritis Foundation, and two funded by the State of California expand the research on the impact of the health care system to persons with systemic lupus erythematosus (SLE). These grants have resulted in the development of large panel of persons with this condition (close to 1,200 at present) who have been followed for seven years and who will, with present funding, be followed for at least four more. The SLE panel has been the subject of at least fifteen papers on the effect of various aspects of the health care system on utilization and outcomes. The R01 was recently refunded, this time solely by NIAMS, to test the extent to which differences among physicians in the quality of care for SLE account for disparities in outcomes by race/ethnicity and socioeconomic status.

The two large panel studies in RA and SLE, in turn, led to the successful competition for a P60 Grant, funded by NIAMS, for a Multidisciplinary Clinical Research Center (MCRC), for which Dr. Yelin is the Principal Investigator. The grant was extended for a sixth year (until two years from March 2010) based on meritorious accomplishment.

Dr. Yelin has also been involved in studies documenting the economic and social impacts of chronic disease and disability. As part of this research, he has been the lead author on two cohorts of the National Arthritis Data Task Force, convened by NIAMS and the CDC to establish the prevalence and impact of musculoskeletal disorders. More recently, he has worked with staff at CDC to develop a new method to assess the increment in direct and indirect costs associated with arthritis beyond the costs that would be expected in the absence of the conditions. This work has resulted in several publications in the premier rheumatology journal, Arthritis and Rheumatism, and in the CDC’s Morbidity and Mortality Weekly Report. Dr. Yelin also authored the chapter in the culminating document from the Bone and Joint Decade on the economic impact of musculoskeletal disease.

Finally, Dr. Yelin has been an active participant in the California Health Benefits Review Program (CHBRP). CHBRP, authorized by AB1996 and subsequently reauthorized twice, provides money to the Office of the Vice President of Health Affairs of the University of California System to analyze the medical effectiveness and public health and economic impact of proposed health insurance mandates. Dr. Yelin has recently been appointed Vice Chair of CHBRP and directs the UCSF Center, housed in the Institute for Health Policy Studies, which does the analysis of the evidence of medical effectiveness for proposed health insurance mandates. Since its inception in 2004, CHBRP has completed analyses of more than 60 proposed mandates covering such services as asthma education, smoking cessation, Alzheimer’s medications, chiropractic care, substance abuse treatment, post-mastectomy care, and transplantation among persons with HIV.
Honors and Awards
  • President's Award, American College of Rheumatology-Association of Rheumatology Health Professionals, 2010
  • Clarke Award for Outstanding Research, Arthritis Foundation, 2003
  • Clarke Award for Outstanding Research, Arthritis Foundation, 2003
  • Elected to Membership, National Academy of Social Insurance, 1999
  • Arthritis Investigator Award, American College of Rheumatology, 1998
  • Distinguished Scholar Award, American College of Rheumatology-Association of Rheumatology Health Professionals, 1995
  1. Socioeconomic Status, Health Care, and Outcomes in Systemic Lupus Erythematosus.
  2. A Policy to Do Better Next Time: Lessons Learned From the COVID-19 Pandemic.
  3. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus.
  4. Longitudinal Study of Fatigue, Stress, and Depression: Role of Reduction in Stress Towards Improvement in Fatigue.
  5. Prevalence of Arthritis and Rheumatoid Arthritis in Coal Mining Counties of the U.S.
  6. The Impact of Frailty on Changes in Physical Function and Disease Activity Among Adults With Rheumatoid Arthritis.
  7. Quality-Adjusted Life-Years Lost Due to Physical Inactivity in the United States Osteoarthritis Population.
  8. Patient Reported Outcomes Predict Mortality in Lupus.
  9. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus.
  10. An update on the burden of musculoskeletal diseases in the U.S.
  11. Response to the Letter to the Editor by Khullar and colleagues about our manuscript.
  12. Opening Salvo.
  13. Experience and Context Shape Patient and Clinician Goals For Treatment of Rheumatoid Arthritis: A Qualitative Study.
  14. Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis.
  15. The Relationship between Poverty and Mortality in Systemic Lupus Erythematosus.
  16. Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis.
  17. Medical Expenditures and Earnings Losses Among US Adults With Arthritis in 2013.
  18. Depression Risk in Young Adults With Juvenile- and Adult-Onset Lupus: Twelve Years of Followup.
  19. Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.
  20. Socioeconomic Predictors of Incident Depression in Systemic Lupus Erythematosus.
  21. A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in Systemic Lupus Erythematosus.
  22. Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment.
  23. Relationship Between Process of Care and a Subsequent Increase in Damage in Systemic Lupus Erythematosus.
  24. Reply.
  25. Cervical Spinal Fracture and Other Diagnoses Associated With Mortality in Hospitalized Ankylosing Spondylitis Patients.
  26. Is frailty a relevant concept in SLE?
  27. Frailty and reduced physical function go hand in hand in adults with rheumatoid arthritis: a US observational cohort study.
  28. Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis.
  29. Patient goals in rheumatoid arthritis care: A systematic review and qualitative synthesis.
  30. Serum biomarkers of inflammation and muscle strength among women with systemic lupus erythematosus.
  31. Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity.
  32. Breast cancer in systemic lupus.
  33. The burden of musculoskeletal diseases in the United States.
  34. Use of Low-Literacy Decision Aid to Enhance Knowledge and Reduce Decisional Conflict Among a Diverse Population of Adults With Rheumatoid Arthritis: Results of a Pilot Study.
  35. Computer use, language, and literacy in safety net clinic communication.
  36. Poverty, Depression, or Lost in Translation? Ethnic and Language Variation in Patient-Reported Outcomes in Rheumatoid Arthritis.
  37. National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia.
  38. Association Between Clinician Computer Use and Communication With Patients in Safety-Net Clinics.
  39. Role of Sleep Disturbance, Depression, Obesity, and Physical Inactivity in Fatigue in Rheumatoid Arthritis.
  40. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.
  41. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
  42. Efficiency Gains for Rheumatology Consultation Using a Novel Electronic Referral System in a Safety-Net Health Setting.
  43. Muscle Strength and Changes in Physical Function in Women With Systemic Lupus Erythematosus.
  44. A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis.
  45. Interactions between patients, providers, and health systems and technical quality of care.
  46. Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty.
  47. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus.
  48. Muscle strength, muscle mass, and physical disability in women with systemic lupus erythematosus.
  49. The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter.
  50. Relationships between driving distance, rheumatoid arthritis diagnosis, and disease-modifying antirheumatic drug receipt.
  51. Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritis.
  52. English language proficiency, health literacy, and trust in physician are associated with shared decision making in rheumatoid arthritis.
  53. Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study.
  54. Educational and vocational outcomes of adults with childhood- and adult-onset systemic lupus erythematosus: nine years of followup.
  55. Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study.
  56. Ethnically diverse patients' perceptions of clinician computer use in a safety-net clinic.
  57. Non-lymphoma hematological malignancies in systemic lupus erythematosus.
  58. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.
  59. Not better but quite good: effects on work loss of combination treatment for rheumatoid arthritis with and without biological agents.
  60. Risk adjustment for health care financing in chronic disease: what are we missing by failing to account for disease severity?
  61. Missed opportunities for depression screening in patients with arthritis in the United States.
  62. Breast cancer in systemic lupus erythematosus.
  63. Pain as a risk factor for disability or death.
  64. Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey.
  65. Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.
  66. Cancer risk in systemic lupus: an updated international multi-centre cohort study.
  67. Lymphoma risk in systemic lupus: effects of disease activity versus treatment.
  68. Poor knowledge of methotrexate associated with older age and limited English-language proficiency in a diverse rheumatoid arthritis cohort.
  69. Sex differences in assessment of obesity in rheumatoid arthritis.
  70. Mediators of the socioeconomic gradient in outcomes of adult asthma and rhinitis.
  71. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.
  72. Compromised access to prescriptions and medical care because of cost among US adults with arthritis.
  73. European genetic ancestry is associated with a decreased risk of lupus nephritis.
  74. Introduction to special issue of best practices in rheumatology: health economics of musculoskeletal diseases.
  75. The economic burden of systemic lupus erythematosus.
  76. Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus.
  77. Lower health literacy is associated with poorer health status and outcomes in chronic obstructive pulmonary disease.
  78. Both pulmonary and extra-pulmonary factors predict the development of disability in chronic obstructive pulmonary disease.
  79. Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care.
  80. Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus.
  81. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes.
  82. Validity of brief screening tools for cognitive impairment in rheumatoid arthritis and systemic lupus erythematosus.
  83. Longitudinal study of the impact of incident organ manifestations and increased disease activity on work loss among persons with systemic lupus erythematosus.
  84. Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey.
  85. Self-management skills in adolescents with chronic rheumatic disease: A cross-sectional survey.
  86. Impact of obesity on functioning among women with systemic lupus erythematosus.
  87. Differences in activity limitation, pain intensity, and global health in patients with rheumatoid arthritis in Sweden and the USA: a 5-year follow-up.
  88. Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics.
  89. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus.
  90. Using the Center for Epidemiologic Studies Depression Scale to screen for depression in systemic lupus erythematosus.
  91. Adult outcomes of childhood-onset rheumatic diseases.
  92. Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus.
  93. Introduction to special theme: vascular comorbidity in the rheumatic diseases.
  94. Long-term patterns of depression and associations with health and function in a panel study of rheumatoid arthritis.
  95. Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function.
  96. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.
  97. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus.
  98. Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis.
  99. Evaluating quality of life in patients with asthma and rhinitis: English adaptation of the rhinasthma questionnaire.
  100. Depression in patients with rheumatoid arthritis: description, causes and mechanisms.
  101. Introduction to special section: quality of care in the rheumatic diseases.
  102. Development of disability in chronic obstructive pulmonary disease: beyond lung function.
  103. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy.
  104. Onset of depressive symptoms among adults with asthma: results from a longitudinal observational cohort.
  105. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.
  106. Estimating medical costs attributable to osteoarthritis in the US population: comment on the article by Kotlarz et al.
  107. Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators.
  108. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis.
  109. Role of community and individual characteristics in physician visits for persons with systemic lupus erythematosus.
  110. An integrated model of environmental factors in adult asthma lung function and disease severity: a cross-sectional study.
  111. Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study.
  112. Disability in valued life activities among individuals with COPD and other respiratory conditions.
  113. Frequent use of the emergency department among persons with systemic lupus erythematosus.
  114. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus.
  115. Influence of anxiety on health outcomes in COPD.
  116. Depressive symptoms in middle age and the development of later-life functional limitations: the long-term effect of depressive symptoms.
  117. Clinical trial registration and publication of randomized controlled trials.
  118. Health-related quality of life and employment among persons with systemic lupus erythematosus.
  119. Measurement of COPD severity using a survey-based score: validation in a clinically and physiologically characterized cohort.
  120. Ambulatory visit utilization in a national, population-based sample of adults with osteoarthritis.
  121. Screening for depression in chronic obstructive pulmonary disease.
  122. The child, grown, becomes independent.
  123. Translating medical effectiveness research into policy: lessons from the California Health Benefits Review Program.
  124. The impact of disability on depression among individuals with COPD.
  125. Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis.
  126. Socioeconomic status, race and COPD health outcomes.
  127. The COPD Helplessness Index: a new tool to measure factors affecting patient self-management.
  128. Introduction to special section: epidemiology of the rheumatic diseases.
  129. Trends in medical care expenditures of US adults with arthritis and other rheumatic conditions 1997 to 2005.
  130. Pain, functional limitations, and aging.
  131. Depression and health-related quality of life in chronic obstructive pulmonary disease.
  132. Do school-based asthma education programs improve self-management and health outcomes?
  133. Further exploration of the links between occupational exposure and chronic obstructive pulmonary disease.
  134. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume.
  135. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
  136. Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists.
  137. The impact of SHS exposure on health status and exacerbations among patients with COPD.
  138. A quality indicator set for systemic lupus erythematosus.
  139. Depression, medication adherence, and service utilization in systemic lupus erythematosus.
  140. Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample.
  141. Exposure to traffic: lung function and health status in adults with asthma.
  142. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.
  143. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus.
  144. The COPD severity score: a dynamic prediction tool for health-care utilization.
  145. Subclinical disability in valued life activities among individuals with rheumatoid arthritis.
  146. Patterns of psychosocial risk and long-term outcomes in rheumatoid arthritis.
  147. Performance of self-reported occupational exposure compared to a job-exposure matrix approach in asthma and chronic rhinitis.
  148. COPD as a systemic disease: impact on physical functional limitations.
  149. Valued life activity disability played a significant role in self-rated health among adults with chronic health conditions.
  150. Out-of-pocket payments in arthritis: spur to prudent purchasing or red herring?
  151. Risk factors for death in adults with severe asthma.
  152. The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus.
  153. Disability in valued life activities among individuals with systemic lupus erythematosus.
  154. Introduction to special section: cost and social and psychological impact of rheumatic diseases.
  155. Pulmonary function and the risk of functional limitation in chronic obstructive pulmonary disease.
  156. Effects of asthma education on children's use of acute care services: a meta-analysis.
  157. Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort.
  158. Effect of arthritis in middle age on older-age functioning.
  159. Socioeconomic gradients in tiotropium use among adults with COPD.
  160. Impact of memory impairment on employment status in persons with systemic lupus erythematosus.
  161. Impact of perceived neighborhood problems on change in asthma-related health outcomes between baseline and follow-up.
  162. Workplace policies and prevalence of knee osteoarthritis: the Johnston County Osteoarthritis Project.
  163. Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus.
  164. Medicaid and access to care among persons with systemic lupus erythematosus.
  165. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997.
  166. Impact of health maintenance organizations and fee-for-service on health care utilization among people with systemic lupus erythematosus.
  167. Prevalence and correlates of arthritis-attributable work limitation in the US population among persons ages 18-64: 2002 National Health Interview Survey Data.
  168. Work disability in rheumatic diseases.
  169. Work dynamics among persons with systemic lupus erythematosus.
  170. Body composition and functional limitation in COPD.
  171. The influence of perceived control of asthma on health outcomes.
  172. Risk factors for work disability in severe adult asthma.
  173. Negative life events and quality of life in adults with asthma.
  174. Journal policies on authorship and disclosures.
  175. Directly measured secondhand smoke exposure and COPD health outcomes.
  176. An analysis of California Assembly Bill 2185: mandating coverage of pediatric asthma self-management training and education.
  177. Evaluating medical effectiveness for the california health benefits review program.
  178. Journal policies on authorship and disclosures.
  179. Measuring disease-specific quality of life in obstructive airway disease: validation of a modified version of the airways questionnaire 20.
  180. Perceived neighborhood problems and quality of life, physical functioning, and depressive symptoms among adults with asthma.
  181. Work life of persons with asthma, rhinitis, and COPD: a study using a national, population-based sample.
  182. Area-level socio-economic status and health status among adults with asthma and rhinitis.
  183. Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis.
  184. Functioning and psychological status among individuals with COPD.
  185. Exposure to vapors, gas, dust, or fumes: assessment by a single survey item compared to a detailed exposure battery and a job exposure matrix.
  186. New journal policy regarding registration of clinical trials.
  187. Impact of managed care on the use of biologic agents for rheumatoid arthritis.
  188. Development and validation of a survey-based COPD severity score.
  189. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease.
  190. Impact of the home indoor environment on adult asthma and rhinitis.
  191. Is early intervention worth it?
  192. Health-related quality of life in adult rhinitis: the role of perceived control of disease.
  193. The association between occupational factors and adverse health outcomes in chronic obstructive pulmonary disease.
  194. Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates.
  195. Functional limitations and well-being in injured municipal workers: a longitudinal study.
  196. Reconstituting people or reconstituting work? The conundrum of occupational epidemiology.
  197. The impact of managed care on health care utilization among adults with asthma.
  198. Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma?
  199. Performance of valued life activities reflected asthma-specific quality of life more than general physical function.
  200. Cost of musculoskeletal diseases: impact of work disability and functional decline.
  201. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis.
  202. The occupational burden of chronic obstructive pulmonary disease.
  203. Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal.
  204. A comprehensive study of the direct and indirect costs of adult asthma.
  205. Effects of physician-related factors on adult asthma care, health status, and quality of life.
  206. The costs of arthritis.
  207. Exposure to indoor combustion and adult asthma outcomes: environmental tobacco smoke, gas stoves, and woodsmoke.
  208. Perceived control of asthma and quality of life among adults with asthma.
  209. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis.
  210. The influence of chronic respiratory conditions on health status and work disability.
  211. Focusing interventions for disability among patients with rheumatoid arthritis.
  212. The prevalence and impact of managed care for persons with rheumatoid arthritis in 1994 and 1999.
  213. A national study of medical care expenditures for respiratory conditions.
  214. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis : data from a population-based survey.
  215. Measurement of environmental tobacco smoke exposure among adults with asthma.
  216. The work impact of asthma and rhinitis: findings from a population-based survey.
  217. A national study of medical care expenditures for musculoskeletal conditions: the impact of health insurance and managed care.
  218. Activity loss and the onset of depressive symptoms: do some activities matter more than others?
  219. Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.
  220. Asthma and smoking status in a population-based study of California adults.
  221. Acknowledgement and corrections for flawed data.
  222. Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity.
  223. Retraction.
  224. Retraction.
  225. Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
  226. Predictors of cigarette smoking and smoking cessation among adults with asthma.
  227. Re: The work dynamics of adults with asthma. 1999. Yelin E., Henke J. , Katz P., Eisner M., Blanc P. Am. J. Ind. Med. 35:472-480.
  228. Reanalysis of Blanc PD et al, "Use of herbal products, coffee or black tea, and over-the-counter medications as self treatments among adults with asthma".
  229. The direct cost of rheumatoid arthritis.
  230. The prevalence and impact of accommodations on the employment of persons 51-61 years of age with musculoskeletal conditions.
  231. Examining specialty care.
  232. Health insurance characteristics and health care evaluations among persons with rheumatic diseases in California.
  233. Access to and utilization of primary care services among HIV-infected women.
  234. The Marks Asthma Quality of Life Questionnaire: further validation and examination of responsiveness to change.
  235. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.
  236. The association between occupation and asthma in general medical practice.
  237. Work dynamics of adults with asthma.
  238. Transitions in employment, morbidity, and disability among persons ages 51-61 with musculoskeletal and non-musculoskeletal conditions in the US, 1992-1994.
  239. Persistent increases of BAL neutrophils as a predictor of mortality following lung transplant.
  240. Report of the OMERACT task force on economic evaluation. Outcome Measures in Rheumatology.
  241. Assessment of asthma severity in adults with asthma treated by family practitioners, allergists, and pulmonologists.
  242. Predictors of rate of return to work after surgery for carpal tunnel syndrome.
  243. Environmental tobacco smoke and adult asthma. The impact of changing exposure status on health outcomes.
  244. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition.
  245. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.
  246. Pulmonary and allergy subspecialty care in adults with asthma. Treatment, use of services, and health outcomes.
  247. Use of herbal products, coffee or black tea, and over-the-counter medications as self-treatments among adults with asthma.
  248. The earnings, income, and assets of persons aged 51-61 with and without musculoskeletal conditions.
  249. Variation among rheumatologists in clinical outcomes and frequency of office visits for rheumatoid arthritis.
  250. Perceived control of asthma: development and validation of a questionnaire.
  251. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings.
  252. Self-reported carpal tunnel syndrome: predictors of work disability from the National Health Interview Survey Occupational Health Supplement.
  253. Dr. Morgan's parable.
  254. The impact on unemployment of an intervention to increase recognition of previously untreated anxiety among primary care physicians.
  255. Asthma, employment status, and disability among adults treated by pulmonary and allergy specialists.
  256. Occupational asthma in a community-based survey of adult asthma.
  257. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates.
  258. Musculoskeletal conditions and employment.
  259. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups.
  260. The transition to managed care: implications for the rheumatology community.
  261. Access to medical care among persons with musculoskeletal conditions. A study using a random sample of households in San Mateo County, California.
  262. Work disability in adults with cystic fibrosis.
  263. The development of depressive symptoms among women with rheumatoid arthritis. The role of function.
  264. Mortality risk among elderly workers.
  265. Life activities of persons with rheumatoid arthritis with and without depressive symptoms.
  266. Making work more central to work disability policy.
  267. Impact of the American Health Security Act of 1993.
  268. Work disability among adults with asthma.
  269. Gender, disability, and employment.
  270. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis.
  271. Correlates of fatigue in older adults with rheumatoid arthritis.
  272. Arthritis. The cumulative impact of a common chronic condition.
  273. Health policy and musculoskeletal conditions.
  274. Labor force participation among persons with musculoskeletal conditions, 1970-1987. National estimates derived from a series of cross-sections.
  275. What's inside the team care box? Is it the parts, the connections, the attention, or the Gestalt?
  276. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis.
  277. The impact of HIV-related illness on employment.
  278. The recent history and immediate future of employment among persons with disabilities.
  279. Transitions in health status among community-dwelling elderly people with arthritis. A national, longitudinal study.
  280. A summary of the impact of musculoskeletal conditions in the United States.
  281. Health care research and technology.
  282. The economic impact of the rheumatic diseases in the United States.
  283. Displaced concern: the social context of the work-disability problem.
  284. Work disability among cancer patients.
  285. A question of value: measuring the impact of chronic disease.
  286. The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with rheumatoid arthritis and osteoarthritis compared to controls.
  287. The work dynamics of the person with rheumatoid arthritis.
  288. Work disability among persons with musculoskeletal conditions.
  289. Risk factors for hospitalization and surgery in patients with rheumatoid arthritis: implications for capitated medical payment.
  290. Health outcomes for a chronic disease in prepaid group practice and fee for service settings. The case of rheumatoid arthritis.
  291. The myth of malingering: why individuals withdraw from work in the presence of illness.
  292. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices.
  293. Social and economic impacts of four musculoskeletal conditions. A study using national community-based data.
  294. Is health care use equivalent across social groups? A diagnosis-based study.
  295. The impact of chronic disease: a sociomedical profile of rheumatoid arthritis.
  296. Work disability in rheumatoid arthritis: effects of disease, social, and work factors.
  297. Toward an epidemiology of work disability.
  298. Social problems, services and policy for persons with chronic disease: the case of rheumatoid arthritis.
  299. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs.
  300. Rheumatology manpower in California. Approaches to assessment of quantitative sufficiency.
  301. The university rheumatic disease clinic: provider and patient receptions of cost.
  302. Resources for the care of arthritics in a nonmetropolitan community. Redding, California.